tbuckley/cabot-search huggingface dataset:
Worth a Second Look
Authors: Tyler M. Berzin, Norton J. Greenberger, Bruce D. Levy, Joseph Loscalzo
Journal: New England Journal of Medicine (2012)

A 72-year-old man presented to his physician for evaluation of fatigue and weight loss. Over the previous 8 months, the patient had lost 16 kg (35 lb) and had begun having up to 10 loose stools per day. There was no history of blood in the stool, fever, chills, or rash.
P167 Outcomesand Predictors Of Mortality In Cancer Patients With Incidental Pulmonary Embolism
Authors: D. Grant, J. Franklin, L. Watts, N. Rahman, F. Gleeson
Journal: Thorax (2014)

<h3>Objectives</h3> Incidental pulmonary emboli (iPE) are detected in a significant minority of contrast CT scans performed during the management of patients with cancer. These patients are reported to have an increased mortality compared to matched controls. This study investigates outcomes and predictors of mortality following iPE. <h3>Methods</h3> Reports of all contrast-enhanced CT scans including the chest, excluding dedicated CT pulmonary angiography, performed between 1st May 2012 and 30th September 2013, were searched for prospectively identified iPE. Clinical data was collected from multiple sources, including clinic letters, discharge summaries, and the hospital patient database. Patients presenting with acute symptoms consistent with PE or those already receiving therapeutic anticoagulation were excluded. Potential clinical and radiological predictors of mortality were defined pre-hoc and tested using Student’s t-test and Cox proportional-hazard regression. <h3>Results</h3> There were 160 cancer patients with iPE. Anticoagulation treatment was given in 97% of cases. Overall 30-day and 6-month mortality following iPE was 20.6% (95% confidence interval 15.0–27.6%) and 52.5% (44.8–60.1%), respectively. Increased 30-day and 6-month mortality was observed in scans performed on inpatients compared to outpatients (38.2% vs 11.4%, p = 0.0004 and 78.2% vs 40.0%, p &lt; 0.0001). 6-month mortality was also increased if this was a new diagnosis of malignancy at the time of the CT scan compared to patients with known malignancy (69.4% vs 46.0%, p = 0.0046), or if metastases were present at the time of CT scan (58.3% vs 26.7%, p = 0.0012). There were 86 (53.8%) central (main or lobar pulmonary arteries), 60 (37.5%) segmental, and 14 (8.8%) subsegmental pulmonary emboli. No significant mortality difference was observed between these radiological features. <h3>Conclusion</h3> This study has assessed potential poor prognostic features in patients with cancer and iPE. Despite the vast majority receiving therapeutic anticoagulation, there is a high 30-day and 6-month mortality. The benefits of conventional treatment in this clinical situation are as yet unclear.
HEART FAILURE PATIENTS EVALUATED IN THE EMERGENCY DEPARTMENT: PERSONALIZATION OF CARE USING THE INTERMOUNTAIN HF READMISSION RISK SCORE
Authors: Deborah Budge, Jose Benuzillo, Kismet Rasmusson, Jennifer Nixon, Benjamin Horne, Michael M. Woodruff, Robert J. Bunnell, Donald Lappe
Journal: Journal of the American College of Cardiology (2015)
Profiles and prognostic values of LDH isoenzymes in patients with non-Hodgkin’s lymphoma
Authors: C Dumontet, J Drai, J Bienvenu, E Neidhardt Berard, C Thieblemont, F Bouafia, F Bayle, I Moullet, G Salles, B Coiffier
Journal: Leukemia (1999)
Abstract 682: Synergistic effects of CG200745 combining with Gemcitabine and/or Erotinib in pancreatic cancer.
Authors: Seonggu Ro, Jang-Won Hong, Sool-Ki Kwon, Hyunju Cha, Dong Sub Jung, Ho-Jin Chang, Joong Myung Cho
Journal: Cancer Research (2013)

Abstract CG200745 is a HDAC inhibitor at the final stage of phase I clinical trial. In the current human studies with patient with terminal solid tumors, CG200745 is showing highly desirable PK and safety profiles. Actually, the AUC/dose of CG200745 is the highest among all the clinical stage HDAC inhibitors. CG200745 is more distributed in tumor tissue that in plasma. Moreover, SD's (stable disease) were observed even in single dose study. Currently, we are planning phase II studies using regimens combining CG200745 and existing therapy in patients with solid tumors. As a choice of indications, pancreatic cancer was considered based on biological studies and observation in phase I clinical studies.Thus, cellular and xenograft studies of CG200745 using pancreatic cancer cell lines have been carried out in our laboratories. In these studies, treatments of CG200745 combining with gemcitabine and/or erotinib show clear synergistic effects. These results indicate that the combination of CG200745 with existing therapy can be a promising intervention for pancreatic cancer. Citation Format: Seonggu Ro, Jang-Won Hong, Sool-Ki Kwon, Hyunju Cha, Dong Sub Jung, Ho-Jin Chang, Joong Myung Cho. Synergistic effects of CG200745 combining with Gemcitabine and/or Erotinib in pancreatic cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 682. doi:10.1158/1538-7445.AM2013-682
Tc-99m MAG3 Scintigraphy in Unusually Dilated Bilateral Extrarenal Pelves
Authors: GULGUN BUYUKDERELI, SHERIF HEIBA, SHAHENDA SALEM, JONAS F. SANTIAGO, GAURAV GOSWAMI, SUMAN JANA, HUSSEIN M. ABDEL-DAYEM
Journal: Clinical Nuclear Medicine (2000)

BUYUKDERELI, GULGUN M.D.; HEIBA, SHERIF M.D.; SALEM, SHAHENDA M.D.; SANTIAGO, JONAS F. M.D.; GOSWAMI, GAURAV M.D.; JANA, SUMAN M.D..; ABDEL-DAYEM, HUSSEIN M. M.D. Author Information
SAT0024 Use of Biologic Drugs and Clinical Effectiveness of Care of Early RA in Two Clinics with Different Treatment Tradition in Their T2T Approach
Authors: T. Sokka, G. Haugeberg, T. Rannio, I. J. Hansen, D. M. Soldal, J. Asikainen, P. Hannonen
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> In early RA, EULAR recommends a conventional monotherapy (with MTX) as the 1<sup>st</sup> DMARD and an addition of a biologic drug in case of inefficacy. Due to high medication costs, these recommendations can be followed in very few countries. Most rheumatology clinics have to manage with the optimal use of inexpensive conventional DMARDs in their T2T approach. <h3>Objectives</h3> To compare the use of DMARDs, biologics and the clinical effectiveness of care of early RA in two rheumatology clinics with different traditions to use of biologics and DMARDs. <h3>Methods</h3> Patients with a new diagnosis of RA in 2007-11 were identified in databases of two rheum. clinics in two countries, and followed until end of 2012. Similarities between the clinics include the size of background population, T2T-approach in care with remission as the treatment target, multidisciplinary care with patient education of T2T, and an electronic monitoring at all visits. Clinical data were compared between the clinics; interval between diagnosis and initiation of a biologic drug was analyzed using Kaplan-Meier statistics. <h3>Results</h3> Included were 499 pts in Clinic1 and 519 in Clinic2 with comparable baseline values and demographics, better outcomes in Clinic2, and different treatment strategies (Table) with earlier use of biologics in Clinic1; Figure; thin line Clinic1, bold line Clinic2, p&lt;0.001. <h3>Image/graph</h3> <h3>Conclusions</h3> The use of biologics vary between countries due to affordability, availability and acceptability. Our results confirm that good clinical results can be achieved in early RA applying T2T strategy in a real world setting using biologics in a minority of patients and that strategy is more important than the drugs used. Furthermore, these results, in line with those of recent clinical trials concerning an active use of conventional DMARDs suggest that EULAR recommendations of the drug treatment of RA should be re-visited. <h3>Disclosure of Interest</h3> None Declared
Do 18F-FDG PET/CT Parameters in Oropharyngeal and Oral Cavity Squamous Cell Carcinomas Indicate HPV Status?
Authors: Ayse Tuba Karagulle Kendi, Kelly Magliocca, Amanda Corey, Dana C. Nickleach, James Galt, Kristin Higgins, Jonathan J. Beitler, Mark W. El-Deiry, J. Trad Wadsworth, Patricia A. Hudgins, Nabil F. Saba, David M. Schuster
Journal: Clinical Nuclear Medicine (2015)

Objective The aim of this study was to explore the relationship of PET/CT parameters with human papillomavirus (HPV) status of oropharyngeal (OP) and oral cavity (OC) squamous cell carcinomas (SCCs). Patients and Methods We retrospectively reviewed 39 patients with OC and OP-SCC who underwent staging 18F-FDG PET/CT. PET/CT parameters were measured for the primary tumor and the hottest involved node, including SUVmax, SUVmean, SUVpeak, metabolic tumor volume, total lesion glycolysis, standardized added metabolic activity (SAM), and normalized SAM. Patient characteristics were compared between HPV positive (HPV+) and negative (HPV−) groups. Receiver operating characteristic analysis was used to dichotomize PET/CT parameters into high and low. Logistic regression models predicting HPV status were fit for each PET/CT parameter. Results The HPV+ group was composed of 18 patients all with OP-SCC; the HPV− group consisted of 21 patients, 4 OP cancer patients and 17 OC cancer patients. The HPV+ group had a higher proportion of N2 stage (94% vs 43%; P < 0.001). Nodal PET/CT parameters were higher in the HPV+ group (P < 0.01); this difference was not present for the primary lesion. After adjusting for sex and age, the association of higher nodal SUVmax (odds ratio [OR], 9.67), SUVmean (OR, 10.48), SUVpeak (OR 9.67), metabolic tumor volume (OR, 14.52), total lesion glycolysis (OR, 11.84), and SAM, normalized SAM (OR, 16.21) with HPV+ status remained statistically significant (P < 0.05). Conclusions Nodal PET/CT parameters predict HPV status. High nodal FDG uptake should raise suspicion for positive HPV status in the evaluation of the primary lesion.
Abstract P4-03-03: Feasibility study of a new volume navigation system-guided breast biopsy method for incidental enhancing lesions detected by breast contrast-enhanced magnetic resonance imaging
Authors: M Takahashi, H Jinno, T Hayashida, M Nemoto, A Tanimoto, Y Kitagawa
Journal: Cancer Research (2012)

Abstract Background: Incidental enhancing lesions (IELs) undetected by conventional imaging such as mammography and ultrasonography (US) have been reported in 16–29% of patients undergoing subsequent breast contrast-enhanced magnetic resonance imaging (CE-MRI). We recently assessed IELs by performing breast biopsies using a volume navigation system (V-Navi) which synchronizse real-time US images with reconstructed CE-MRI data side-by-side on the same monitor. The aim of this retrospective study was to evaluate the feasibility of V-Navi-guided biopsy method as an IEL diagnostic procedure. Methods: We performed breast biopsies on 333 patients after mammography, US and CE-MRI (GE Signa Excite HDx 1.5T, USA) examinations between January 2011 and May 2012 at Keio University Hospital. Patients with IELs detected by CE-MRI underwent a second-look US and a bilateral CE-MRI in the supine position in order to achieve the same position as in the US. CE-MRI data was then fused with real-time US images using a V-Navi (Logiq E9, GE Healthcare, USA). When an IEL was identified, we performed a V-Navi-guided vacuum-assisted needle biopsy (11G) or an excisional biopsy after V-Navi-guided marking. Results: US-guided and stereo-guided breast biopsies were performed on 77.2% (257) and 16.8% (56) of the 333 patients, respectively. Twenty patients (6.0%) had IELs detected by CE-MRI and all such IELs were identified by the V-Navi. Sixteen (80%) of those 20 patients had IELs clearly detected by the V-Navi and underwent V-Navi-guided needle biopsies. The four remaining patients (20%) had IELs that were not clearly detected by the V-Navi and they underwent excisional biopsies. The median IEL size was 8.8mm (range, 5.0–48) and the median procedure time for V-Navi-guided needle biopsies was 42 minutes. No major complications were encountered in any of the cases. Histopathologically, nine IELs (45%) had malignant findings of invasive ductal carcinoma (5/20) and ductal carcinoma in situ (4/20) and 11 IELs (55%) had benign findings of fibrocystic disease (10/20) and intraductal papilloma (1/20). Conclusion: The V-Navi-guided breast biopsy method was shown to be a safe and effective diagnostic method for the assessment of IELs detected by breast CE-MRI. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-03-03.
POINT-OF-CARE ASSESSMENT OF NOAC-INDUCED ANTICOAGULATION: THE NOVEL HAEMONETICS TEG 6S SYSTEM
Authors: Paul A. Gurbel, Kevin Bliden, Martin Gesheff, Adina Muresan, Carlos G. Lopez-Espina, Paresh Shah, Eli Cohen, Gabriel Raviv, Marc Doubleday, Fowzia Zaman, Udaya Tantry
Journal: Journal of the American College of Cardiology (2015)
Abstract 256: Involvement of ERK and ROS in CLEFMA-induced apoptosis in lung cancer cells
Authors: Vivek R. Yadav, Kaustuv K. Sahoo, Vibhudutta Awasthi
Journal: Cancer Research (2012)

Abstract CLEFMA (4-[3,5-bis(2-chlorobenzylidene-4-oxo-piperidine-1-yl)-4-oxo-2-butenoic acid) is novel synthetic molecule with potent growth inhibitory activity in human cancer cells. Our microarray gene expression analysis suggested that it induces oxidative stress in lung adenocarcinoma H441 cells but not in normal lung fibroblasts. That oxidative stress is a triggering mechanism for both apoptotic and autophagic cell death has been supported by several recent reports. Compared to normal cells, the cancer cells are more vulnerable to oxidative stress-induced cell death because of their high metabolic activity, increased likelihood of electron escape during oxidative phosphorylation and overburdened antioxidant system. In this study, we tested our hypothesis that CLEFMA-induced apoptotic cell death was dependent on the accompanying increase in oxidative stress in H441cells. Methods: Inhibition of cell growth by CLEFMA (10 µM) was estimated by MTT or hexosaminidase assay. ROS production, cell cycle and apoptotic cell population were assessed by flow cytometry. The phosphorylation levels of extracellular signal-regulated kinase (ERK1/2), p38 and JNK1/2 were examined by Western blotting. N-acetylcysteine (NAC, 5 mM) and PD98059 (5 mM) were used as ROS scavenger and ERK1/2 inhibitors, respectively. The molecular markers of apoptosis were analyzed by RT-PCR and immunobloting. Results: NCI-DTP program confirmed anticancer activity of CLEFMA in 60 human cancer cell lines. CLEFMA-treated H441 cells showed typical molecular signatures of apoptosis- upregulated pro-apoptotic and downregulated anti-apoptotic genes. There was time-dependent activation of caspases 3/7, PARP cleavage and BAX; the expression of anti-apoptotic XIAP1 and BCL-xL was reduced, whereas pro-apoptotic p53 was increased. Since BID was not activated, it appears that CLEFMA works through intrinsic apoptosis pathway. CLEFMA also induced sustained activation of ERK, p38 and JNK. The pharmacologic inhibition of ERK, but not that of p38 and JNK, resulted in decreased anti-proliferative activity of CLEFMA. ERK inhibition with PD98059 abrogated CLEFMA-induced apoptosis. The sustained ERK activation was found to be associated with the inhibition of dual specificity phosphatase, DUSP6, expression. Treatment with ROS scavenger NAC abrogated CLEFMA-induced cell death, ERK activation and pro-apoptotic biomarkers, and reinstated DUSP6 expression. Conclusion: From the results of this study, we conclude that CLEFMA-induces apoptosis by enhancing oxidative stress in the cancer cells, and that the accompanying prolonged ERK activation is required for CLEFMA-induced H441 cell death. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 256. doi:1538-7445.AM2012-256
Leucine-Induced Hypoglycemia
Authors: Heskel M. Haddad, William C. Roberts, Pacita Pronove, Frederic C. Bartter
Journal: New England Journal of Medicine (1962)

SPONTANEOUS hypoglycemia in infancy may, on rare occasions, be precipitated by the ingestion of casein, L-leucine or isovaleric acid, an intermediary metabolite of leucine.1 2 3 4 Recently, this phenomenon of "leucine-induced hypoglycemia" was observed to be associated with a rise in plasma insulin level.5 , 6 A case of leucine-induced hypoglycemia in an infant who, at autopsy, showed hyperplasia of pancreatic islet cells is reported below. In addition the patient had massive bilateral subdural hematomas, with cerebral atrophy.Case ReportP.C., a 3 1/2-month-old female Negro infant, was admitted to the Clinical Center of the National Institutes of Health on July 13, 1959, because . . .
Abstract 5646: Allele-specific shRNA to Nanog family members inhibits 3-D growth of colorectal carcinoma through the intrinsic apoptotic pathway
Authors: Jingyu Zhang, Snorri S. Thorgeirsson, J. Milburn Jessup
Journal: Cancer Research (2012)

Abstract Nanog and NanogP8 modulate stemness of human colorectal cancer (CRC) as measured by directly affecting spherogenicity, tumorigenicity and metastatic potential. As a result, we tested whether targeting NanogP8 (the dominant Nanog member expressed in human CRC lines and liver metastases) by specific lentiviral (LV) shRNA inhibits the growth of CRC in 3-D spheroids in suspension culture. We first designed allele-specific shRNAs to NanogP8 and Nanog, genes that differ only in 5 nucleotides in a 915 nt ORF, and demonstrated that the shRNA to NanogP8 (shNp8-1) and Nanog (shNG-1) specifically inhibited their target in PA-1, a human embryonal carcinoma line expressing only Nanog, or CX-1, a CRC that expresses predominantly NanogP8. When Clone A or CX-1 CRC cells transfected with Luc2 were cultured for 24 hours in suspension in serum-free medium (SFM), transduced with LV shNP8-1, shNG-1 or a control shRNA (shNeg) at a multiplicity of infection (MOI) 8 and cultured for another 72 hours in SFM, all of the LV vectors transduced 40 - 75% of the cells in 3-D constructs. shNp8-1 transduction significantly reduced the mass of cells and luciferase activity by 50%. Apoptosis was induced because CRC treated with shNp8-1 had significantly more annexin V+ cells than did shNEG or untreated parental cells. Previous work in our lab demonstrated that caspase 8 was important in anoikis - the apoptosis caused by suspension of cells whose growth generally requires adherence. Caspase 3, 8 and 9 activity was measured by fluorogenic substrates in Clone A and CX-1 cells at 4 days of suspension culture, 3 days after LV treatment. Caspase 3 activity was increased by shNp8-1 by 2.5 to 3-fold in both CX-1 and Clone A compared to untreated cells. shNp8-1 treatment increased Caspase 9 activity by ∼50% in both CRC lines compared to untreated cells whereas shNEG and shNG-1 transduction did not increase Caspase 9 activity significantly. Treatment with a Caspase 9 peptidomimetic blocked apoptosis and increased CX-1 survival significantly. When cells were harvested at the end of the 4 day apoptosis assay and replated in a standard colony forming assay, CX-1 cells transduced with shNp8-1 LV produced 33% fewer colonies than did the shNEG and shNG-1 controls. These results indicate that shNp8-1 transduction may activate apoptosis through a Caspase 9-dependent pathway and that this treatment may have long term effects that inhibit tumor regrowth after treatment. Supported by Center for Cancer Research funds and Department of Defense IDEA grant W81XWH-11-1-0327. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5646. doi:1538-7445.AM2012-5646
Response to Drs. Chu and Smart Concerning Breast Cancer Screening in Women Under 50 Years
Authors: D. M. EDDY
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article Response to Drs. Chu and Smart Concerning Breast Cancer Screening in Women Under 50 Years Get access DAVID M. EDDY DAVID M. EDDY Center for Health Policy Research and Education Duke UniversityP.O. Box GM, Duke Station Durham, NC 27706 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 10, 22 May 1989, Pages 813–814, https://doi.org/10.1093/jnci/81.10.813 Published: 22 May 1989
A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma.
Authors: F. S. Hodi, P. A. Friedlander, M. B. Atkins, D. F. McDermott, D. P. Lawrence, N. Ibrahim, X. Wu, J. Zhou, A. Giobbie-Hurder, G. Murphy, T. Hollman, E. Velazquez, S. Russell, P. Dipiro, J. T. Yap, A. D. Van Den Abbeele
Journal: Journal of Clinical Oncology (2011)

8511 Background: CTLA-4 blockade with ipilimumab demonstrated a survival advantage in advanced melanoma. Ipilimumab induces an immune mediated tumor vasculopathy. In addition to angiogenic effects, VEGF is a potent immune suppressor of antigen presenting cells. Therefore, we performed the first combination study to investigate potential synergies of ipilimumab and bevacizumab. Methods: Patients (pts) were eligible with stage III unresectable or stage IV disease, no bowel or CNS metastases, ECOG PS 0 or 1, > 4 wks from prior therapy, adequate end organ function, no autoimmune or bleeding problems. Pts received ipilimumab every 3 weeks IV x 4 then q12 weeks, and bevacizumab q 3 weeks. Pts could continue if good PS with up to 40% increase in the sum of the longest diameter and no more than 2 new target lesions. Cohort 1 comprised 10 mg/kg ipilimumab plus 7.5 mg/kg bevacizumab. If ≥3/5 pts did not experience DLT then cohort 2 could be enrolled at 10 mg/kg ipilimumab plus 15 mg/kg bevacizumab. An additional 12 patients could be treated at MTD. Results: 22 pts treated with 21 pts currently evaluable. Side effects included giant cell arteritis(1), hypophysitis(3), thyroiditis(4), grade 3-4 hepatitis(2), bilateral uveitis(2), and grade 2 colitis(2); 5 pts required systemic steroids and stopping treatment. All toxicities resolved. PET revealed early response activity and perfusion CT demonstrated persistent decreased tumor blood flow. Best overall response to date includes 8 partial responses and 6 stable disease. All responses are durable (>6mos). Median TTP has not yet been achieved. Post-treatment biopsies in 12 pts revealed activated vessel endothelium with extensive T cell trafficking not seen with ipilimumab alone, as well as non-productive central angiogenesis. Peripheral blood monitoring revealed marked increase in CD4/CCR7/CD45RO central memory cells in majority of patients, not seen with ipilimumab alone. Conclusions: Ipilimumab plus bevacizumab can be safely administered, with management of noted toxicities. Clinical activity and correlatives suggest synergistic effects, with 14/21 pts experiencing clinical benefit. This combination merits further exploration, with additional efforts underway.